Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA

Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA

Source: 
Fierce Pharma
snippet: 

Olumiant's list of potential indications just got a bit shorter, courtesy of lackluster data and gridlock at the FDA.


Eli Lilly and Incyte are pulling the plug on Olumiant in lupus, the companies announced Friday. Chalk that one up to mixed results from two of the med’s pivotal phase 3 trials.

Likewise, Olumiant’s application in moderate-to-severe atopic dermatitis could be destined for a complete response letter (CRL), the partners warned. Lilly blamed that potential outcome on the fact that it hasn’t aligned with the FDA on the indicated population for Olumiant’s would-be label expansion.